Skip to content

Start investing now

Invest directly by choosing one of the brokers below

Start investing now

Invest directly by choosing one of the brokers below

CANC Oncology ETF

Investing behind the prevention and cure of cancer

5 Reasons to Consider

Impact icon

Impact

Investors can provide capital to companies pioneering cures and early detection of cancer
Innovation icon

Innovation

The life sciences industry is still in the early stages of a revolution in oncology innovations - from CAR-T cell therapies to bi-specific antibodies - powered by biological insights and growing capabilities
Research Expertise icon

Research Expertise

The fund conducts deep and comprehensive research, in an effort to identify those companies that deliver breakthrough solutions at attractive valuations
Growth icon

Growth

Oncology is an increasingly prioritized therapeutic class with treatment spend expected to grow substantially, driven by an aging population; this secular growth trend also tends to be insulated from economic cycles
Uncorrelated icon

Uncorrelated

Performance of many biotechnology companies relies on clinical success which is an uncorrelated source of return

Fund Overview

Fund Details

As of
  • Primary Exchange Nasdaq
  • Ticker CANC
  • Cusip 87975E701
  • Median Bid/Ask Spread (30 Day)
  • Fund Inception Date 1692057600000
  • Gross Expense Ratio 0.0099
  • Net Expense Ratio* 0.0075
  • Shares Outstanding
  • Number of Holdings
  • Investment Adviser Tema Global Limited
  • Sub-Investment Adviser NEOS Investments, LLC
  • Distributor Foreside Fund Services, LLC
  • Portfolio Manager David K. Song, MD, PhD, CFA
*Contractual expense cap for net expense ratio of 0.75% is in effect through 06/30/2024

Fund Summary

The actively managed Tema Oncology ETF seeks to provide long-term growth by investing in companies operating in the oncology industry. Cancer is the second deadliest killer but is on the brink of a revolution in therapeutics and diagnosis. Genetic sequencing and other forces are leading to a productivity surge, with oncology leading the way in new drug approvals. The growing complexity of scientific discovery, regulation and a surge in investment opportunities requires expertise to navigate this exciting chapter in human development.

Portfolio Breakdown

Top 10 holdings

As of
  • Company% Nav

Country Breakdown

Industry Breakdown

Fund Insights & Media

Tema launches actively managed oncology ETF:  investing in the cancer life-science revolution Featured Image

Tema launches actively managed oncology ETF: investing in the cancer life-science revolution

Prices & Performance

Monthly Quarterly

CANC

3 months

YTD

1 Year

3 Years

5 Years

Since Inception

NAV
Market Price

As of

Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. Returns for periods of less than one year are not annualized.

The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date because there is no bid/ask spread until the fund starts trading.

 

CANC Nav/Market Price

NAV
Market Price
NAV Change (1D)
Market Price Change (1D)
Median Bid/Ask Spread (30 Day)
Premium/Discount

Premium/Discount

Chart Table

Days Traded at Nav

Days Traded at Premium

Days Traded at Discount

As of

How to Buy